Newer antidepressants and other nonhormonal agents for the treatment of hot flashes

Comprehensive Therapy

Volumn 31, Issue 3, 2005, Pages 224-236

  Perez, Domingo G ^a   Loprinzi, Charles L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA TOCOPHEROL; ANDROGEN; ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; BELLADONNA ALKALOID; BELLARGAL; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; CYTOCHROME P450 2D6; DRUG METABOLITE; ESTROGEN; FLUOXETINE; GABAPENTIN; GESTAGEN; ISOFLAVONE; LYSERGIDE; MEDROXYPROGESTERONE; MIRTAZAPINE; PAROXETINE; PROGLUMIDE; RALOXIFENE; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SERTRALINE; TAMOXIFEN; UNINDEXED DRUG; VENLAFAXINE;

ANXIETY; APPETITE DISORDER; BREAST CANCER; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; CONSTIPATION; DISTRESS SYNDROME; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; EDEMA; FATIGUE; HOT FLUSH; HUMAN; INCREASED APPETITE; INSOMNIA; MOOD DISORDER; NAUSEA; NONHUMAN; PROSTATE CANCER; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SOYBEAN; SWEATING; THERMOREGULATION; TREATMENT OUTCOME; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; AMINES; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; CIMICIFUGA; CLONIDINE; CYCLOHEXANECARBOXYLIC ACIDS; DRUG INTERACTIONS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HOT FLASHES; HUMANS; ISOFLAVONES; PHYTOTHERAPY; VITAMIN E;

EID: 23844534137     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1385/COMP:31:3:224     Document Type: Review

References (122)

1. McKinlay SM, Jeffreys M. The menopausal syndrome. Br J Prev Soc Med 1974;28:108-115.
2. Tataryn IV, Lomax P, Meldrum DR, Bajorek JG, Chesarek W, Judd HL. Objective techniques for the assessment of postmenopausal hot flashes. Obstet Gynecol 1981;57:340-344.
3. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836-840.
4. Roberts J, Chambers LF, Blake J, Webber C. Psychosocial adjustment in post-menopausal women. Can J Nurs Res 1992; 24:29-46.
5. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353:571-580.
6. Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA. Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage 1998;16:327-333.
7. Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage 2000;19:436-445.
8. Berg G, Gottwall T, Hammar M, Lindgren R. Climacteric symptoms among women aged 60-62 in Linkoping, Sweden in 1986. Maturitas 1988;10:193-199.
9. Carpenter J, Adrykowski M, Cordova M, et al. Hot flashes in post-menopausal women treated for breast carcinoma. Cancer 1998;82:1682-1691.
10. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-1847.
11. Rabin DS, Cipparrone N, Linn ES, Moen M. Why menopausal women do not want to take hormone replacement therapy. Menopause 1999;6:61-67.
12. Notelovitz M, Lenihan JP, McDermott M, Keber IJ, Nanavati N, Arce J. Initial 17-beta-estradioldose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726-731.
13. Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
14. Creasman WT. Estrogen and cancer. Gynecol Oncol 2002;86:1-9.
15. Lacey JV Jr., Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer JAMA 2002;288:334-341.
16. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-741.
17. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998;92:472-479.
18. Cobleigh MA, Berris RF, Bush T, et al. Estrogen replacement therapy in breast cancer survivors: a time for change. JAMA 1994;272:540.
19. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997;65:89.
20. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999;17:1482.
21. DiSaia PJ, Grosen EA, Kurosaki T, et al. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996;174:1494.
22. Natrajan PK, Soumakis K, Gambrell RD Jr. Estrogen replacement therapy in women with previous breast cancer. Am J Obstet Gynecol 1999;181:288.
23. Beckmann MW, Jap D, Djahansouzi S, et al. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 2001;60:199.
24. Col NF, Hirota LK, Orr RK, et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357.
25. O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754.
26. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma. Cancer 2002;95:1817.
27. Creasman WT. Estrogen replacement therapy: Is previously treated cancer a contraindication? Obstet Gynecol 1991;77:308.
28. Bullock JL, Massey FM, Gambrell RD Jr. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-168.
29. Morrison JC, Martin DC, Blair RA, et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99-104.
30. Albrecht BH, Schiff I, Tulchinsky D, Ryan KJ. Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes. Am J Obstet Gynecol 1981;139:631-635.
31. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-352.
32. Young RL, Kumar NS, Goldzieher JW. Management of menopause when estrogen cannot be used. Drugs 1990;40:220-230.
33. Quella SK, Loprinzi CL, Sloan JA, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998;82:1784-1788.
34. Lobo RA, McCormick W, Singer F, Roy S. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 1984;63:1-5.
35. Bullock JL, Massey FM, Gambrell RD Jr. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165-168.
36. Morrison JC, Martin DC, Blair RA, et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99-104.
37. Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of post-menopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002;6:883-888.
38. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-228.
39. Guttuso TJ Jr. Gabapentin's effects on hot flashes and hypothermia. Neurology 2000;54:2161-2163.
40. Loprinzi CL, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002;77:1159-1163.
41. Thummala AR, Griggs J, Rosenblatt J, et al. Pilot study using gabapentin on tamoxifen-induced hot flashes in women with breast cancer [abstract]. Proc Am Soc Clin Oncol 2002;21:362a (Abstract no. 1444).
42. Guttuso T Jr. Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-345.
43. Pandya KJ, Roscoe J, Pajon E, et al. A preliminary report of a double blind placebo controlled trial of gabapentin for control of hot flashes in women with breast cancer. A University of Rochester Cancer Center CCOP study. Proc Am Soc Clin Oncol 2004;23:8015.
44. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16:495-500.
45. Goldberg RM, Loprinzi C, O'Fallon Jr, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-158.
46. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in post-menopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-793.
47. Pepping J. Black cohosh: Cimicifuga racemosa. Am J Health Syst Pharm 1999;156:1400-1402.
48. Liske E, Wustenber P. Therapy of climacteric complaints with cimicguga racemosa: herbal medicine with clinically proven evidence. Menopause 1998;5:250.
49. Borelli F, Izzo AA, Ernst E. Pharmacological effects of Cimicifuga racemosa. Life Sciences 2003;73:1215-1229.
50. Burdette JE, Liu J, Chen S, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem 2003;51:5661-5670.
51. Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat 2002;76:1-10.
52. Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. Antiestrogenic activities of Cimicifuga racemosa extracts. JSteroid Biochem Mol Biol 2002;80:125-130.
53. Einbond LS, Masahito S, Xiao D, et al. Growth inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells. Breast Cancer Res Treat 2004;83:221-231.
54. Hostankska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apopptosis. Breast Cancer Res Treat 2004;84:151-160.
55. Freudenstein J, Dasenbrock C, Niblein T. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract. Cancer Res 2002;62:3448-3452.
56. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739-2745.
57. Pockaj BA, Loprinzi CL, Sloan JA, et al. Pilot Evaluation of Black Cohosh for the Treatment of Hot Flashes in Women. Cancer Investigation 2004;22:515-521.
58. Pockaj BA, Gallagher J, Loprinzi CL, et al. Phase III double-blinded, randomized trial to evaluate the use of black cohosh in the treatment of hot flashes: a North Central Cancer Treatment Group study. Proc Am Soc Clin Oncol 2005;23:7325 (Abstract 8013).
59. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18:1068-1074.
60. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in post-menopausal women: a multicenter, double-blind, randomized, placebo-controlled study [published correction appears in Menopause. 2000;7:422]. Menopause. 2000;7:236-242.
61. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr 2001;131(11 Suppl):3095S-3108S.
62. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes [published correction appears in Obstet Gynecol. 2001;98:702]. Obstet Gynecol 1998;91:6-11.
63. Bergmans MG, Merkus JM, Corbey RS, Schellekens LA, Ubachs JM. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 1987;9:227-234.
64. Loprinzi CL, Pisanski TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377-2381
65. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet 2000;356:2059-2063.
66. Barton D, LaVasseur B, Lorpinzi C, et al. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum 2002;29:33-40.
67. Quella SK, Loprinzi CL, Sloan J, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. The Journal of Urology 1999;162:98-102.
68. Shafgat A, et al. A phase II study of venlafaxine for the treatment of hot flashes in men undergoing androgen deprivation for prostate cancer. Proc Am Soc Clin Oncol 2004;22:7655 (Abstract 8148).
69. Loprinzi CL, et al. Medroxyprogesterone acetate (MPA) versus venlafaxine for hot flashes: a North Central Cancer Treatment Group Trial. 2005 Annual Meeting of the American Society of Clinical Oncology, Abstract no.
70. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583.
71. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22.
72. Weitzner MA, Moncello J, Jacobsen PB, et al. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002;23:337-345.
73. Stearns V, Beebe KL, Iyengar M, et al. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834.
74. Loprinzi CL, Barton DL, Carpenter LA, et al. Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc 2004;79:1247-1251.
75. Barton DL, Loprinzi CL, Novotny P, et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003;1:47-51.
76. Carpenter LA, et al. Pilot evaluation of citalopram for alleviation of hot flashes in women with inadequate hot flash control with venlafaxine. 2005 Annual Meeting of the American Society of Clinical Oncology, Abstract no. 8148.
77. Kimmick GG, Lovato J, McQuellon R, et al. Randomized, placebo-controlled study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. American Society of Medical Oncology Annual Meeting 2001, Abstract no. 1585.
78. Perez DG, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. The Journal of Supportive Oncology 2004;2:50-56.
79. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985;22:293-312.
80. Aksel S, Schomberg DW, Tyrey L, Hammond CB. Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause. Am J Obstet Gynecol 1976;126:165-169.
81. Abe T, Furuhashi N, Yamaya Y, Wada Y, Hoshiai A, Suzuki M. Correlation between climacteric symptoms and serum levels of estradiol, progesterone, follicle-stimulating hormone, and luteinizing hormone. Am J Obstet Gynecol 1977;129:65-67.
82. Chakravarti S, Collins WP, Newton JR, Oram DH, Studd JW. Endocrine changes and symptomatology after oophorectomy in pre-menopausal women. Br J Obstet Gynaecol 1977;84:769-775.
83. Hutton JD, Jacobs HS, Murray MA, James VH. Relation between plasma oestrone and oestradiol and climacteric symptoms. Lancet 1978;1:678-681.
84. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-2358.
85. Casper RF, Yen SS, Wilkes MM. Menopausal flushes: a neuroendocrine link with pulsatile luteninizing hormone secreation. Science 1979;205:823-825.
86. Tataryn IV, Meldrum DR, Lu KH, Frumar AM, Judd HL. LH, FSH and skin temperaure during the menopausal hot flash. J Clin Endocrinol Metab 1979;49:152-154.
87. Casper RF, Yen SS. Menopausal flushes: effect of pituitary gonadotropin desensitization by a potent luteinizing hormone-releasing factor agonist. J Clin Endocrinol Metab 1981;53:1056-1058.
88. Menon V, Edwards RL, Lynch SS, Butt WR. Luteinizing hormone releasing hormone analogue in treatment of hypergonadotrophic amenorrhoea. Br J Obstet Gynaecol 1983;90:539-542.
89. Mulley G, Mitchell JR, Tattersall RB. Hot flushes after hypophysectomy. BMJ 1977;2:1062.
90. Meldrum DR, Erlik Y, Lu JK, Judd HL. Objectively recorded hot flushes in patients with pituitary insufficiency. J Clin Endocrinol Metab 1981;52:684-688.
91. Freedman RR, Krell W. Reduced thermoregulatory null zone in post-menopausal women with hot flashes. Am J Obstet Gynecol 1999;181:66-70.
92. Kronenberg F, Downey JA. Thermoregulatory physiology of menopausal hot flashes: a review. Can J Physiol Pharmacol 1987;65:1312-1324.
93. Rosenberg J, Larsen SH. Hypothesis: pathogenesis of post-menopausal hot flush. Med Hypotheses 1991;35:349-350.
94. Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002;23:41-100.
95. Halbreich U, et al. Estrogen augments serotonergic activity in post-menopausal women. Biol Psychiatry 1995;37:434-441.
96. Friedman SA, Hirsh SE. Extreme hyperthermia after LSD ingestion. JAMA 1971;217:1549-1550.
97. Liskow B. Extreme hyperthermia from LSD. JAMA 1971;218:1049.
98. Manzerra P, Brown IR. Time course of induction of a heat shock gene (hsp70) in the rabbit cerebellum after LSD in vivo: involvement of drug-induced hyperthermia. Neurochemical Research 1990;15:53-59.
99. Murakami N, Sakai Y, Ooki S. Behavioral thermoregulation in rats during hyperthermia induced by lysergic acid diethylamide. Neurosci Lett 1980;20:105-108.
100. Blessing WW, Seaman B. 5-hydroxytryptamine(2A) receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats. Neuroscience 2003;117:939-948.
101. Mazzola-Pomietto P, Aulakh CS, Wozniak KM, Hill JL, Murphy DL. Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology 1995;117:193-199.
102. Nisijima K, Yoshino T, Takano K, Kato S. Potent serotonin (5-HT) (2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 2001;890:23-31.
103. Waldinger MD, Berendsen HH, Schweitzer DH. Treatment of hot flashes with mirtazapine: four case reports. Maturitas 2000;36: 165-168,
104. Berendsen HHG, Kloosterboer HJ. Oestradiol and mirtazapine restore the disturbed tail-temperature os oestrogen-deficient rats. Eur J Pharmacol 2003;482:329-333.
105. Sipe K, Leventhal L, Burroughs K, Cosmi S, Johnston GH, Deecher DC. Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction. Brain Res 2004;1028:191-202.
106. Mazzola-Pomietto P, Aulkah CS, Wozniak KM, Murphy DL. Evidence tha m-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2C receptors. Psychopharmacology (Berl) 1996;123:333-339.
107. Weiner DM, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exper Ther 2001;299:268-276.
108. Summer BE, Fink G. Estrogen increases the density of 5-HT2A receptors in the cerebral cortex and nucleus accumbens in the female rat. J Steroid Biochem Mol Biol 1995;54:15-20.
109. Cyr M, Bosse R, Di Paolo T. Gonadal hormones modulate 5-HT2A receptors: emphasis on the rat frontal cortex. Neuroscience 1998;83:829-836.
110. Biegon A, Recehes A, Snyder L, McEwen BS. Serotonergic and noradrenergic receptor in the rat brain: modulation by chronic exposure to ovarian hormones. Life Sci 1983;32:2015-2021.
111. Rosier A, Dupont P, Peuskens J, et al. Visualization of loss of 5-HT2A receptors with age in healthy volunteers using [18F] altanserin and positron emission tomographic imaging. Psychiatry Res 1996;68:11-22.
112. Kugaya A, Epperson CN, Zoghbi S, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in post-menopausal women. Am J Psych 2003;160:1522-1524.
113. Moses-Kolko EL, Berga SL, Greer PJ, Smith G, Cidis Meltzer C, Drevets WC. Widespread increases of cortical serotonin type 2A receptor availability after hormone therapy in euthymic posmenopausal women. Fertil Steril 2003;80:554-559.
114. Moses EL, Drevets WC, Smith G, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding; a PET study. Biol Psychiatry 2000;48:854-860.
115. Summer BEH, Fink G. Testosterone as well as estrogen increases serotonin(2A) receptor mRNA and binding site densities in the male rat brain. Mol Brain Res 1998;59:205-214.
116. Van Amelsvoort T, Compton J, Murphy D. In vivo assessment of the effects of estrogen on human brain. Trends Endocrinol Metab 2001;12:273-276.
117. Hunter MS, Grunfeld EA, Mittal S, et al. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology 2004;13:769-778.
118. Summer BE, Grant KE, Rosie R, Hegele-Härtung C, Fritzemeier KH, Fink G. Effects of tamoxifen on serotonin transporter and 5-hydroxitryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Mol Brain Res 1999;73:119-128.
119. Stearns V, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-1764.
120. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39.
121. Goetz MP, Safgren S, Goldberg RM, et al. Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52. 2005 American Society of Clinical Oncology Annual Meeting, abstract in press.
122. Sloan J, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodological lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290.